Resistance fuelling contact lens infections

Article

A study published in the January issue of Antimicrobial Agents & Chemotherapy, has found that the high proportion of corneal infections linked to contact lens solutions are fuelled and made resistant to treatment by the formation of a highly resistant structure of microbial cells held together with a glue-like matrix material, called biofilms.

A study published in the January issue of Antimicrobial Agents & Chemotherapy, has found that the high proportion of corneal infections linked to contact lens solutions are fuelled and made resistant to treatment by the formation of a highly resistant structure of microbial cells held together with a glue-like matrix material, called biofilms.

Fungal keratitis is commonly caused by Fusarium species and less commonly by Candida species. Recent outbreaks of Fusarium keratitis were associated with contact lens wear, specifically ReNu with MoistureLoc contact lens care solution (Bausch & Lomb) and biofilm formation on contact lenses or lens cases were proposed to play a role in this outbreak.

In response to this, Mahmoud Ghannoum and colleagues from the Center for Medical Mycology, University Hospitals Case Medical Center, Cleveland, USA developed an in vitro model for contact lens-associated fungal biofilm.

In their study, the research team developed and characterized in vitro models of biofilm formation on various soft contact lenses using three species of Fusarium and Candida albicans (C. albicans). The contact lenses tested were etafilcon A, galyfilcon A, lotrafilcon A, balafilcon A, alphafilcon A, and polymacon.

The results showed that clinical isolates of Fusarium and C. albicans formed biofilms on all types of lenses tested and that the biofilm architecture varied with the lens type. Moreover, differences in hyphal content and architecture were found between the biofilms formed by these fungi. It was also discovered that two recently isolated keratitis-associated fusaria formed robust biofilms, while the reference ATCC 36031 strain (recommended by the International Organization for Standardization guidelines for testing of disinfectants) failed to form a biofilm. Furthermore, using the developed in vitro biofilm model, the team showed that phylogenetically diverse planktonic Fusaria and Candida were susceptible to MoistureLoc and MultiPlus. However, Fusarium biofilms exhibited reduced susceptibility against these solutions in a species- and time-dependent manner.

As a result of this study, it is advised that industry ensure their multipurpose solutions are effective against biofilms.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.